Inotiv to Acquire Plato BioPharma for ~$15.0M
Shots:
- Inotiv to acquire Plato BioPharma for $15.0M that consist of $10.0M in cash- $2.0M in Inotiv's common shares (57-587) based on the average closing price for 20 trading-day period ends on Sept 29- 2021- $3.0M in unsecured promissory notes
- The acquisition will bolster PBI’s growing discovery operations in the Boulder- Colorado & expands its business to supports the growing demand for services
- After closing the transaction- Inotiv expects to retain all of PBI's 34 employees. Plato focusses on cardiovascular- renal- pulmonary- and hepatic therapeutic areas
| Ref: Globe Newswire | Image: Inotiv
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com